Ubs Group Ag Belite Bio, Inc Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in Belite Bio, Inc stock. As of the latest transaction made, Ubs Group Ag holds 551 shares of BLTE stock, worth $35,743. This represents 0.0% of its overall portfolio holdings.
Number of Shares
551
Previous 12,207
95.49%
Holding current value
$35,743
Previous $770,000
95.32%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding BLTE
# of Institutions
19Shares Held
270KCall Options Held
0Put Options Held
0-
Gamma Investing LLC Foster City, CA122KShares$7.94 Million0.01% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL83.6KShares$5.42 Million0.02% of portfolio
-
State Street Corp Boston, MA20.1KShares$1.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA12.8KShares$827,2870.0% of portfolio
-
Jpmorgan Chase & CO New York, NY8.16KShares$529,4680.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.61B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...